Buy Corglycard® ampoules 0.06%, 1 ml, 10 pcs
  • Buy Corglycard® ampoules 0.06%, 1 ml, 10 pcs

Corglycard®

Experimental plant GNTsLS
1788 Items
2019-09-19
Dosage form
Brand & Manufacturer
Package Size
$22.44
Quantity
  • done All payments are SSL encrypted
  • done Full Refund if you haven't received your order
  • done International shipping to the USA, UK and Europe

Clinical Pharmacology

Purified preparation of lily of the valley leaves May and its varieties. Cardiac glycoside, has a positive inotropic effect. This is due to the direct inhibitory effect of Na + / K + ATP-ase on the cardiomyocyte membrane, which leads to an increase in the intracellular content of sodium ions and, accordingly, a decrease in potassium ions. The increased content of sodium ions causes the activation of sodium / calcium metabolism, an increase in the content of calcium ions, as a result of which the force of contraction of the myocardium increases.

As a result of an increase in myocardial contractility, the stroke volume of the blood increases, the final systolic and terminal diastolic volumes of the heart decrease, which, along with an increase in myocardial tone, leads to a reduction in its size and, thus, to a decrease in myocardial oxygen demand.

It has a negative chronotropic effect, reduces excessive sympathetic activity by increasing the sensitivity of cardiopulmonary baroreceptors. Due to the increase in the activity of the vagus nerve, it has an antiarrhythmic effect, due to the decrease in the speed of the impulses passing through the atrioventricular node and the lengthening of the effective refractory period. This effect is enhanced by direct action on the atrioventricular node and sympatholytic action.

The negative dromotropic effect is manifested in an increase in the refractoriness of the atrioventricular (AV) node.

In atrial tachyarrhythmias, cardiac glycosides help to slow down ventricular contractions, prolong diastole, improve intracardiac and systemic hemodynamics. A positive bathmotropic effect is manifested in subtoxic and toxic doses. It has a direct vasoconstrictor effect, which is most clearly manifested in the absence of congestive peripheral edema. At the same time, the indirect vasodilating effect (in response to an increase in the minute volume of blood and a decrease in excessive sympathetic stimulation of vascular tone), as a rule, prevails over direct vasoconstrictor action, resulting in a decrease in total peripheral vascular resistance (OPSS).

When administered intravenously, the action begins after 3-5 minutes and reaches a maximum after 25-30 minutes.

Indications

In the complex treatment of chronic heart failure II-IV functional class (in the presence of clinical manifestations), the tachysystolic form of atrial fibrillation and flutter paroxysmal and chronic course (especially in combination with chronic heart failure).

Composition

1 ml of solution contains:

Active ingredient: Korglikon - 0.60 mg

Excipients: chlorobutanol hydrate, water for injection.

No customer reviews for the moment.

Write your review

Write your review

Corglycard®

Dosage and Administration

IV slowly (within 4-5 min), 0.5-1 ml of 0.06% solution, 2 times a day (for children 2-5 years old - 0.2-0.5 ml, 6-12 years - 0.5-0.75 ml); Before use, diluted in 10 ml or 20 40% dextrose solution or 0.9% NaCl solution. The highest single dose with a / in the introduction - 1 ml daily - 2 ml.

Adverse reactions

Side effects of Corglycon are associated with patient hypersensitivity to cardiac glycosides or overdose. Since the cardiovascular system: arrhythmia, AV blockade.

From the central nervous system and sensory organs: drowsiness, confusion, sleep disturbances, headache, dizziness, delirious psychosis, decreased visual acuity.

From the side of blood-forming organs: thrombocytopenia, thrombocytopenic purpura, nasal bleeding.

On the part of the digestive system: anorexia.

Other: allergic reactions.

Contraindications

Abrupt organic changes in the heart and blood vessels, acute myocarditis, endocarditis, marked cardiosclerosis. Caution is required for thyrotoxicosis and atrial premature beats because of the possibility of its transition to atrial fibrillation.

Drug interactions

Adrenomimetic means. The combined use of ephedrine hydrochloride, epinephrine hydrochloride or norepinephrine hydrotartrate, as well as selective beta-adrenomimetic agents with cardiac glycosides may contribute to the arrhythmia of the heart.

Aminazine and other phenothiazine derivatives. The effect of cardiac glycosides decreases.

Anticholinesterase drugs. With the simultaneous use of anticholinesterase drugs with cardiac glycosides, bradycardia is enhanced. If necessary, it can be eliminated or weakened by the introduction of atropine sulfate.

Glucocorticosteroids. If hypokalemia occurs as a result of prolonged treatment with glucocorticosteroids, the undesirable effect of cardiac glycosides may increase.

Diuretics. When combining diuretics (cause hypokalemia and hypomagnesaemia, but increase the concentration of calcium ions in the blood) with cardiac glycosides, the action of the latter increases. At their simultaneous use it is necessary to adhere to optimum dispensing. You can periodically assign potassium-sparing diuretics (spironolactone, triamteren), which eliminate hypokalemia. However, this may develop hyponatremia.

Potassium preparations. Under the influence of potassium preparations, the undesirable effects of cardiac glycosides are reduced.

Calcium preparations. When treating with cardiac glycosides, parenteral administration of calcium preparations is dangerous, since cardiotoxic effects (cardiac arrhythmias, etc.) are enhanced.

Ethylenediaminetetraacetic acid disodium salt. There is a decrease in the efficiency and toxicity of cardiac glycosides.

Corticotropin preparations. The effect of cardiac glycosides under the influence of corticotropin may increase.

Xanthine derivatives. Caffeine or theophylline drugs sometimes contribute to the arrhythmia of the heart.

Sodium adenosine triphosphate. Sodium adenosine triphosphate should not be administered simultaneously with cardiac glycosides.

Ergocalciferol. When hypervitaminosis caused by ergocalciferol, may increase the action of cardiac glycosides, due to the development of hypercalcemia.

Narcotic analgesics. A combination of fentanyl and cardiac glycosides can cause hypotension.

Naproxen. In healthy people, the combined use of cardiac glycosides with naproxen does not affect the results of psychological testing.

Paracetamol. The clinical significance of this interaction has not been studied enough, but there is evidence of a decrease in kidney excretion of cardiac glycosides under the influence of paracetamol.

Special instructions

The likelihood of intoxication increases with hypokalemia, hypomagnesemia, hypercalcemia, hypernatremia, hypothyroidism, severe dilatation of the heart cavities, pulmonary heart, myocarditis, obesity, old age. In severe mitral stenosis and normo-or bradycardia, heart failure develops due to a decrease in left ventricular diastolic filling.Strofantin, increasing the contractility of the myocardium of the right ventricle, causes a further increase in pressure in the pulmonary artery system, which can provoke pulmonary edema or aggravate left ventricular failure. Patients with mitral stenosis cardiac glycosides prescribed for the addition of right ventricular failure, or in the presence of atrial fibrillation. In WPW syndrome, Korglikon, reducing AV conduction, contributes to conduction of impulses through additional paths - bypassing the AV node, provoking the development of paroxysmal tachycardia. As one of the methods of monitoring the level of digitalization in the appointment of cardiac glycosides, use is made of monitoring their plasma concentration.

  • Brand name: Corglycard®
  • Active ingredient: Lily of the valley leaf glycoside
  • Dosage form: Solution for intravenous administration.
  • Manufacturer: Experimental plant GNTsLS
  • Country of Origin: Russia

8 other products in the same category:

arrow_upward